FMI
AXSM icon

F/M Investments’s Axsome Therapeutics AXSM Stock Holding History

F/M Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Sell
13,268
-27,864
-68% -$4.81M 0.15% 98
2025
Q4 		$7.51M Buy
41,132
+1,637
+4% +$229K 0.29% 88
2025
Q3 		$4.8M Buy
39,495
+7,279
+23% +$820K 0.19% 132
2025
Q2 		$3.36M Buy
+32,216
New +$3.41M 0.12% 182

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

F/M Investments's AXSM Position: Q1 2026 in Review

F/M Investments reduced its Axsome Therapeutics (AXSM) stake by 68% in Q1 2026, selling an estimated $4.81M and leaving 13,268 shares worth $2.24M. The position accounts for 0.15% of the portfolio, ranked #98.

F/M Investments first reported a position in AXSM in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.51M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • F/M Investments held 13,268 shares of Axsome Therapeutics worth $2.24M as of Q1 2026.
  • F/M Investments sold 27,864 Axsome Therapeutics shares in Q1 2026, an estimated $4.81M.
  • Axsome Therapeutics made up 0.15% of F/M Investments's portfolio in Q1 2026, its #98 holding.
  • F/M Investments first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • F/M Investments's Axsome Therapeutics position peaked at $7.51M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.